Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb 28:527:193-194.
doi: 10.1016/j.canlet.2021.12.020.

Reply

Sanjib Chaudhary  1 , Imayavaramban Lakshmanan  1 , Apar Kishor Ganti  2 , Muzafar A Macha  3 , Surinder K Batra  4
Affiliations
Comment

Reply

Sanjib Chaudhary et al. Cancer Lett. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

SKB is one of the co-founders of Sanguine Diagnostics and Therapeutics, Inc. AKG has received consulting fees from AstraZeneca, Jazz Pharmaceuticals, G1 Therapeutics, Blueprint Medicines, Genentech, Flagship Biosciences, Mirati Therapeutics and research support form Takeda. AKG also serves on a DSMC for YMAbs. Other authors declare no potential conflicts of interest.

Comment on

References

    1. Chaudhary S, Pothuraju R, Rachagani S, Siddiqui JA, Atri P, Mallya K, Nasser MW, Sayed Z, Lyden ER, Smith L, Gupta SD, Ralhan R, Lakshmanan I, Jones DT, Ganti AK, Macha MA, Batra SK, Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring, Cancer Letters, 510 (2021) 79–92. - PMC - PubMed
    1. Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K, Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations, Lung Cancer, 127 (2019) 146–152. - PubMed
    1. Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N, Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells, J Exp Clin Cancer Res, 38 (2019) 266. - PMC - PubMed
    1. Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G, A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck, Int J Radiat Oncol Biol Phys, 105 (2019) 132–139. - PubMed
    1. Specenier P, Vermorken J, Afatinib in squamous cell carcinoma of the head and neck, Expert Opin Pharmacother, 17 (2016) 1295–1301. - PubMed